Comparative Pharmacology
Head-to-head clinical analysis: INDERIDE LA 120 50 versus TIMOLOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDERIDE LA 120 50 versus TIMOLOL.
INDERIDE LA 120/50 vs TIMOLOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Propranolol is a nonselective beta-adrenergic receptor antagonist that blocks beta-1 and beta-2 receptors, decreasing heart rate, myocardial contractility, and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits the Na+/Cl- symporter in the distal convoluted tubule, reducing sodium reabsorption and promoting diuresis.
Nonselective beta-adrenergic receptor antagonist (beta-blocker) that competively blocks beta-1 and beta-2 receptors, reducing heart rate, contractility, and cardiac output. In glaucoma, decreases intraocular pressure by reducing aqueous humor production.
One capsule orally once daily, containing 120 mg propranolol HCl and 50 mg hydrochlorothiazide.
0.25-0.5 mg ophthalmic solution instilled twice daily; for oral: 10-20 mg twice daily.
None Documented
None Documented
Clinical Note
moderateTimolol + Digoxin
"Timolol may increase the bradycardic activities of Digoxin."
Clinical Note
moderateTimolol + Digitoxin
"Timolol may increase the bradycardic activities of Digitoxin."
Clinical Note
moderateTimolol + Deslanoside
"Timolol may increase the bradycardic activities of Deslanoside."
Clinical Note
moderateTimolol + Acetyldigitoxin
"Timolol may increase the bradycardic activities of Acetyldigitoxin."
Propranolol: 3-6 hours; Hydrochlorothiazide: 6-15 hours. Note: Inderide LA is an extended-release formulation; effective half-life extended to approximately 8-12 hours for propranolol component.
Terminal half-life: 4-5 hours (healthy adults); prolonged to 7-10 hours in renal impairment, 11-16 hours in hepatic impairment; clinical context: once-daily dosing for hypertension/glaucoma.
Primarily hepatic metabolism (90%+), with <5% excreted unchanged in urine. Biliary/fecal elimination accounts for negligible amounts.
Renal: ~20% unchanged; hepatic metabolism accounts for ~80%, with metabolites excreted renally; minor biliary/fecal elimination (<5%).
Category C
Category A/B
Beta-Blocker/Diuretic Combination
Beta-Blocker